Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Fineline Cube Jul 9, 2026
Company Deals

Xenovector and Jilin University Launch Strategic Partnership to Advance Gene-Edited Pig Organ Transplantation from Breakthrough to Affordable Healthcare

Fineline Cube Jul 9, 2026
Company Deals

Zhejiang Hisun Pharmaceutical and Tigermed Forge Strategic Alliance to Create End-to-End Innovative Drug Development Pipeline

Fineline Cube Jul 9, 2026
Company Deals

Transcenta Returns Select Lilly Assets in Portfolio Restructuring, Retains Blosozumab Rights

Fineline Cube Jul 8, 2026
Company Deals Digital

Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory

Fineline Cube Jul 8, 2026
Policy / Regulatory

China’s National Health Commission Unveils 2026 Essential Medicines List, Adding 116 New Drugs with Full Insurance Coverage

Fineline Cube Jul 9, 2026
Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Fineline Cube Jul 9, 2026
Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Fineline Cube Jul 9, 2026
Company Deals

MGI Tech Partners with Italy’s Negedia to Advance Genomic Sequencing and Spatial Transcriptomics

Fineline Cube Jun 30, 2025

China-based gene sequencing specialist MGI Tech Co., Ltd. announced a collaboration with Italy’s Negedia to...

Policy / Regulatory

China Proposes Healthcare Security Law to Strengthen Medical Insurance System

Fineline Cube Jun 30, 2025

China’s National Healthcare Security Administration (NHSA) last week released the “Healthcare Security Law (draft proposal)”,...

Company Deals

QuantumPharm and Pfizer Expand Collaboration on Advanced Molecular Simulation Platform

Fineline Cube Jun 30, 2025

Shenzhen-based QuantumPharm Inc., known as Xtalpi Inc. (HKG: 2228), has announced an expansion of its...

Company Deals

BlissBio Inc. Files for Hong Kong IPO to Advance Oncology-Focused ADC Pipeline

Fineline Cube Jun 30, 2025

Hangzhou-based oncology-focused clinical-stage biotech BlissBio Inc. has filed for an initial public offering (IPO) with...

Policy / Regulatory

FDA Removes REMS Requirements for BCMA- and CD19-Targeted CAR-T Therapies

Fineline Cube Jun 30, 2025

The U.S. Food and Drug Administration (FDA) last week announced the removal of Risk Evaluation...

Company Deals

ProFound Therapeutics and Novartis Forge Four-Year Partnership for Cardiovascular Drug Targets

Fineline Cube Jun 30, 2025

US-based ProFound Therapeutics announced a four-year partnership with Swiss giant Novartis (NYSE: NVS) to discover...

Company Deals

Diagens Biotech’s AI Imaging Platform iMedImage Makes Hong Kong IPO Debut

Fineline Cube Jun 30, 2025

China-based Hangzhou Diagens Biotechnology Co., Ltd. has filed for an initial public offering (IPO) with...

Company Drug

Pfizer’s Emblaveo Approved by China’s NMPA for Complex Infections

Fineline Cube Jun 30, 2025

US giant Pfizer Inc., (NYSE: PFE) announced that it has received marketing approval from China’s...

Company Drug

Gilead’s Lenacapavir Approved in Hainan for HIV-1 Pre-Exposure Prophylaxis

Fineline Cube Jun 30, 2025

US-based Gilead Sciences, Inc. (NASDAQ: GILD) announced that its HIV pre-exposure prophylaxis (PrEP) drug, lenacapavir,...

Company Deals

GenFleet Therapeutics Files for Hong Kong IPO Amid KRAS Inhibitor Success

Fineline Cube Jun 30, 2025

China-based GenFleet Therapeutics (Shanghai) Inc. has submitted its initial public offering (IPO) application to the...

Company Deals

DK Medtech Partners with Mozarc Medical to Enhance Hemodialysis Access Solutions

Fineline Cube Jun 28, 2025

Suzhou-based DK Medical Technology Co. Ltd., a developer of vascular intervention balloon products, has entered...

Company Drug

ACIP Recommends MSD’s Enflonsia for Infants Under 8 Months to Prevent RSV

Fineline Cube Jun 27, 2025

US pharmaceutical giant Merck, Sharp & Dohme (MSD; NYSE: MRK) revealed that the Advisory Committee...

Others

Viatris Announces Positive Results in VEGA-3 Trial for MR-141 Presbyopia Treatment

Fineline Cube Jun 27, 2025

US-based Viatris (NASDAQ: VTRS) announced positive topline results from the second pivotal Phase III VEGA-3...

Company Medical Device

Jenscare’s LuX-Valve Plus Shows Promising Results in Global TRINITY Study

Fineline Cube Jun 27, 2025

Ningbo-based structural heart disease device maker Jenscare Scientific Co., Ltd (HKG: 9877) announced positive 30-day...

Company Drug

Innovent Biologics’ Mazdutide Gets NMPA Nod for Weight Management

Fineline Cube Jun 27, 2025

China’s National Medical Products Administration (NMPA) has approved Innovent Biologics, Inc.’s (HKG: 1801) mazdutide (IBI362),...

Company Deals

Mabwell Bioscience Partners With Calico Life Sciences on 9MW3811 Development

Fineline Cube Jun 27, 2025

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) is set to enter into a licensing...

Policy / Regulatory

China Raises Subsidy for Basic Public Health Services, Targets Vulnerable Groups

Fineline Cube Jun 27, 2025

China’s National Health Commission (NHC) released the “Notice on Improving Basic Public Health Services in...

Company Drug

Hua Dong Medicine’s HDM2020 Gains NMPA Approval for Clinical Trials

Fineline Cube Jun 27, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received clinical trial approval...

Company Drug

Cutia Therapeutics’ Phase III Results for Lidocaine-Tetracaine Cream to be Presented at CSD Meeting

Fineline Cube Jun 27, 2025

Cutia Therapeutics (HKG: 2487), a dermatology specialist, is set to present the Phase III clinical...

Company Deals

Novartis Completes Acquisition of Regulus Therapeutics for ADPKD Treatment

Fineline Cube Jun 27, 2025

Swiss giant Novartis (NYSE: NVS) announced the completion of its acquisition of U.S.-based Regulus Therapeutics....

Posts pagination

1 … 162 163 164 … 693

Recent updates

  • Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients
  • Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs
  • Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial
  • Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST
  • Changchun High & New Technology’s Subsidiary GenSci Secures NMPA IND Acceptance for GenSci148, First-in-Class VEGF Multi-Blocker for Retinal Vascular Diseases
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Company Drug

Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.